The relationship of rate and pause features to the communicative participation of people living with ALS
- 4 June 2024
- journal article
- research article
- Published by Wiley in Muscle & Nerve
- Vol. 70 (2) , 217-225
Abstract
Introduction/Aims: Many people living with amyotrophic lateral sclerosis (PALS) report restrictions in their day‐to‐day communication (communicative participation). However, little is known about which speech features contribute to these restrictions. This study evaluated the effects of common speech symptoms in PALS (reduced overall speaking rate, slowed articulation rate, and increased pausing) on communicative participation restrictions.Methods: Participants completed surveys (the Communicative Participation Item Bank‐short form; the self‐entry version of the ALS Functional Rating Scale‐Revised) and recorded themselves reading the Bamboo Passage aloud using a smartphone app. Rate and pause measures were extracted from the recordings. The association of various demographic, clinical, self‐reported, and acoustic speech features with communicative participation was evaluated with bivariate correlations. The contribution of salient rate and pause measures to communicative participation was assessed using multiple linear regression.Results: Fifty seven people living with ALS participated in the study (mean age = 61.1 years). Acoustic and self‐report measures of speech and bulbar function were moderately to highly associated with communicative participation (Spearman rho coefficients ranged from rs = 0.48 to rs = 0.77). A regression model including participant age, sex, articulation rate, and percent pause time accounted for 57% of the variance of communicative participation ratings.Discussion: Even though PALS with slowed articulation rate and increased pausing may convey their message clearly, these speech features predict communicative participation restrictions. The identification of quantitative speech features, such as articulation rate and percent pause time, is critical to facilitating early and targeted intervention and for monitoring bulbar decline in ALS.Keywords
Funding Information
- National Institutes of Health (DP2‐MH103909, NIH‐NIDCD K24DC016312, K23DC019179, 1R15DC018944)
This publication has 46 references indexed in Scilit:
- Proceedings of the 22nd Annual Meeting of the Northeast ALS ConsortiumMuscle & Nerve, 2023
- Dextromethorphan/quinidine for the treatment of bulbar impairment in amyotrophic lateral sclerosisAnnals of Clinical and Translational Neurology, 2023
- Rate of speech decline in individuals with amyotrophic lateral sclerosisScientific Reports, 2022
- Verification, analytical validation, and clinical validation (V3): the foundation of determining fit-for-purpose for Biometric Monitoring Technologies (BioMeTs)npj Digital Medicine, 2020
- Design and results of a smartphone‐based digital phenotyping study to quantify ALS progressionAnnals of Clinical and Translational Neurology, 2019
- ALS biomarkers for therapy development: State of the field and future directionsMuscle & Nerve, 2015
- Communicative participation restrictions in multiple sclerosis: Associated variables and correlation with social functioningJournal of Communication Disorders, 2014
- Aspects of speech rate and regularity in Parkinson's diseaseJournal of the Neurological Sciences, 2011
- A Qualitative Study of Interference With Communicative Participation Across Communication Disorders in AdultsAmerican Journal of Speech-Language Pathology, 2011
- The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory functionJournal of the Neurological Sciences, 1999